1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Vertex’s VX-548 For Acute Pain May Be Right On Time For Market

Medicare Policy Change In 2025 Favors Non-Opioids

 
• By Mandy Jackson

The company’s NaV1.8 inhibitor succeeded in Phase III acute pain trials and will be submitted for US FDA approval in mid-2024. It may reach the market in time for Medicare reimbursement changes favoring non-opioids.

Abdominoplasty plastic operation to reduce the abdomen and remove cellulite
VX-548 succeeded in Phase III abdominoplasty and bunionectomy studies • Source: Shutterstock

The closely watched Phase III clinical trials for Vertex Pharmaceuticals Incorporated’s NaV1.8 inhibitor VX-548 in the treatment of moderate-to-severe acute pain following abdominoplasty, bunionectomy and other procedures or events successfully met most of the three studies’ endpoints. As a result, the company plans to submit the drug for US Food and Drug Administration approval by mid-2024 and, if approved, it could reach the market in time for Medicare reimbursement changes favoring non-opioids.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.

More from R&D

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

Could There Be A Cure For Cardiometabolic Disease? Novo Nordisk Foundation Wants To Help Academics Find Out

 
• By Andrew McConaghie

The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.